Abstract
1164
Objectives 4-Borono-2-[18F]fluoro-L-phenylalanine ([18F]FBPA) has been generally prepared according to the method described by Ishiwata et al. (Appl Radiat Isot 1991), in order to study tissue accumulation before boron neutron capture therapy where 4-borono-L-phenylalanine (BPA) is given intravenously as a carrier of 10B to tumor tissue. However, fluorination of BPA with [18F]acetylhypofluorite ([18F]AcOF) in trifluoroacetic acid (TFA), is insufficient for clinical use because of low radiochemical yield (RCY) (20-35%; decay corrected on the based on [18F]AcOF). We devised a novel synthesis of [18F]FBPA in order to improve the RCY.
Methods [18F]AcOF was bubbled into CHCl3 (2 mL) containing N-tert-butoxycarbonyl-BPA tert-butyl ester (N-Boc-BPA(OBut) (42 mg) for 5 min at room temperature (rt). After removal of CHCl3, the residue was dissolved in TFA (1 mL) and stirred for 5 min at rt. The RCY of [18F]FBPA were measured by thin layer chromatography with CHCl3/MeOH/AcOH (3/2/1) as eluent.
Results The protic solvents such as TFA have been generally used as reaction field for the directly aromatic fluorination with [18F]AcOF. However, it is known that the solvents provide significantly [18F]labeled byproducts in fluorination with [18F]AcOF. Whereas, the aprotic solvent has been hardly used in the aromatic fluorination with [18F]AcOF. We selected CHCl3 which is an aprotic solvent as reaction field and N-Boc-BPA(OBut) as a novel precursor. [18F]FBPA was prepared by fluorination of N-Boc-BPA(OBut) with [18F]AcOF in CHCl3, followed by removal of Boc and But groups with TFA. The RCY based on [18F]AcOF was approximately 80% and was 2-4 times higher than that (20-35%) by the method previously employed.
Conclusions The present finding suggested that a novel synthesis of [18F]FBPA may enable increment of the number of cases examined in [18F]FBPA-PET.